{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-161235","form_type":"8-K","ticker":"AURA","cik":"0001501796","company_name":"Aura Biosciences, Inc.","filed_at":"2022-05-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.943391+00:00","generated_at":"2026-06-25T06:17:07.770991+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Aura Biosciences publishes preclinical data on AU-011 + checkpoint inhibitors at ASCO 2022","bullets":["AU-011 combined with immune checkpoint inhibitors showed efficacy against primary tumors and distant metastases in murine models.","Data published as abstract e14544 in 2022 ASCO Annual Meeting proceedings (June 3-7, 2022).","Collaboration with Leiden University Medical Center: survival data suggest potent targeted cytotoxicity on local tumors and metastases.","Potential clinical application for choroidal melanoma and non-muscle invasive bladder cancer (NMIBC)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-161235","json":"https://secwatch.observer/filing/0001193125-22-161235.json","markdown":"https://secwatch.observer/filing/0001193125-22-161235.md","text":"https://secwatch.observer/filing/0001193125-22-161235.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522161235/0001193125-22-161235-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501796/000119312522161235/d348590d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T06:17:07.770991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}